Compare DraftKings Inc (DKNG) vs Novavax Inc (NVAX) Price & Performance

DraftKings (DKNG) trades at $26.45, showing minimal daily movement. The stock exhibits a bullish technical trend with strong moving average signals, supported by a positive cash flow turnaround to $274.40 million in 2025. Revenue growth has been robust, rising from $2.2 billion in 2022 to $6.05 billion in 2025, with the company achieving its first net profit of $3.71 million. Recent expansion into Alberta and the launch of prediction markets highlight ongoing growth initiatives.

The outlook is positive, driven by analyst consensus with a $34.18 price target and 73% buy ratings. Key catalysts include upcoming sports events and product launches, but risks involve high valuation multiples and regulatory scrutiny. Profitability remains nascent, requiring sustained execution to justify current premiums.

Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.

The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.